9 completed, 3 terminated, 2 active not recruiting, 1 unknown. 16 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 9, Terminated 3, Active not recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Unknown 1 |
Follow parsaclisib: new trials by email Literature Review of parsaclisib trials Research Report on parsaclisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) parsaclisib - Lymphoma | Phase 2 | Completed | Incyte Biosciences Japan GK | 42 | 2020-09-30 | 2024-10-23 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib - B-Cell Malignancies | Phase 2 | Active not recruiting | Incyte Corporation | 112 | 2020-08-03 | 2026-06-25 |
| IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma IBI376 - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 81 | 2020-04-07 | 2024-06-05 |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris Parsaclisib - Pemphigus Vulgaris | Phase 2 | Withdrawn | Incyte Corporation | 2019-03-01 | 2019-09-13 | |
| A Study of INCB050465 in Primary Sjögren's Syndrome Parsaclisib - Primary Sjögren's Syndrome | Phase 2 | Completed | Incyte Corporation | 10 | 2019-02-28 | 2021-08-13 |
| A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Parsaclisib - Autoimmune Hemolytic Anemia | Phase 2 | Completed | Incyte Corporation | 25 | 2018-11-21 | 2025-07-11 |
| A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma Parsaclisib - Lymphoma | Phase 2 | Completed | Incyte Corporation | 126 | 2018-03-14 | 2025-03-14 |
| A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Parsaclisib - Lymphoma | Phase 2 | Completed | Incyte Corporation | 110 | 2017-12-18 | 2025-07-11 |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor Parsaclisib - Lymphoma | Phase 2 | Completed | Incyte Corporation | 162 | 2017-11-20 | 2025-03-18 |
| A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Parsaclisib - Lymphoma | Phase 2 | Completed | Incyte Corporation | 60 | 2017-03-02 | 2025-08-22 |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Parsaclisib, Ruxolitinib - MPN (Myeloproliferative Neoplasms) | Phase 2 | Terminated | Incyte Corporation | 74 | 2017-02-08 | 2024-05-01 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies INCB052793, gemcitabine, nab-paclitaxel - Solid Tumors, Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 83 | 2014-09-10 | 2020-04-17 |
Lymphoma, Non-Hodgkin (6) · Lymphoma (5) · Hereditary Sensory and Autonomic Neuropathies (3) · Lymphoma, Follicular (3) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Myeloproliferative Disorders (2) · Recurrence (2) · Anemia, Hemolytic, Autoimmune (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Neoplasm Metastasis (1) · Pemphigus (1) · Primary Myelofibrosis (1)
Incyte Corporation (12) · Incyte Biosciences Japan GK (2) · Fudan University (1) · Innovent Biologics (Suzhou) Co. Ltd. (1)
United States (11) · Italy (7) · France (6) · Spain (6) · Belgium (5) · Poland (5) · United Kingdom (5) · Czechia (4) · Denmark (4) · Germany (4) · Israel (4) · Australia (3) · Austria (3) · Japan (3) · Canada (2)
Kathleen Butler, MD (3) · Fred Zheng, MD (2) · Albert Assad, MD (1) · Claudia Corrado, M.D. (1) · Claudia Corrado, MD (1) · Ekaterine Asatiani, M.D. (1) · Fred Zheng, MD, PhD (1) · Junning Cao (1) · Oliver Manzke, MD (1)
PMID 30803990, PMID 33140664, PMID 38290135, PMID 39435908, PMID 40365847, PMID 41563911
2017 (4), 2016 (1), 2019 (1)